[Form 4] Eli Lilly & Co. Insider Trading Activity
Daniel Skovronsky, EVP, Chief Scientific Officer and President of LRL & LLY Imm at Eli Lilly & Co (LLY), reported a purchase on 08/12/2025 of 1,000 shares of common stock on Form 4. The transaction is coded P for purchase at a weighted average price of $634.405 with execution prices ranging from $634.21 to $634.42. After the reported purchase the filing shows 137,660.112 shares beneficially owned directly. The filing also discloses indirect holdings of 72,359 shares by a trust, 747 shares by the reporting person鈥檚 spouse, and 2,510 shares held in a spousal lifetime access trust transferred on March 10, 2025. The filer disclaims beneficial ownership except to the extent of pecuniary interest.
Daniel Skovronsky, EVP, Chief Scientific Officer e Presidente di LRL & LLY Imm presso Eli Lilly & Co (LLY), ha segnalato l'acquisto in data 08/12/2025 di 1,000 azioni ordinarie nel Form 4. La transazione 猫 contrassegnata con il codice P (acquisto) a un prezzo medio ponderato di $634.405, con prezzi di esecuzione compresi tra $634.21 e $634.42. Dopo l'operazione, il deposito indica la propriet脿 diretta di 137,660.112 azioni. La stessa comunicazione riporta inoltre partecipazioni indirette di 72,359 azioni detenute da un trust, di 747 azioni dal coniuge della persona che effettua la comunicazione, e di 2,510 azioni detenute in un spousal lifetime access trust trasferito il 10 marzo 2025. Il dichiarante rinuncia alla titolarit脿 beneficiaria salvo nella misura dell'interesse patrimoniale.
Daniel Skovronsky, EVP, Chief Scientific Officer y Presidente de LRL & LLY Imm en Eli Lilly & Co (LLY), declar贸 la compra el 08/12/2025 de 1,000 acciones ordinarias en un Formulario 4. La operaci贸n est谩 codificada como P (compra) a un precio medio ponderado de $634.405, con precios de ejecuci贸n entre $634.21 y $634.42. Tras la compra se帽alada, la presentaci贸n muestra 137,660.112 acciones pose铆das directamente. El documento tambi茅n revela tenencias indirectas de 72,359 acciones por un trust, de 747 acciones por el c贸nyuge de la persona declarante, y de 2,510 acciones mantenidas en un spousal lifetime access trust transferido el 10 de marzo de 2025. El declarante renuncia a la titularidad beneficiaria salvo en la medida de un inter茅s pecuniario.
Daniel Skovronsky電� Eli Lilly & Co (LLY)鞐愳劀 EVP, Chief Scientific Officer 瓴� LRL & LLY Imm 雼措嫻 靷灔鞙茧靹� 08/12/2025鞐� Form 4鞐� 1,000欤�鞚� 氤错喌欤茧ゼ 毵れ垬頃� 靷嫟鞚� 鞁犼碃頄堨姷雼堧嫟. 瓯半灅電� 毵れ垬毳� 雮橅儉雮措姅 旖旊摐 P搿� 攵勲霅橃棃鞙茧┌ 臧�欷戫弶攴犼皜瓴╈潃 $634.405, 觳搓舶 臧�瓴╈潃 $634.21鞐愳劀 $634.42 靷澊鞓�鞀惦媹雼�. 鞁犼碃霅� 毵れ垬 鞚错泟 鞝滌稖靹滊鞐愲姅 歆侅爲鞝侅溂搿� 137,660.112欤�毳� 鞁れ 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 氍胳劀鞐愲姅 鞁犿儊鞚� 氤挫湢頃� 72,359欤�, 鞁犼碃鞛愳潣 氚办毎鞛愱皜 氤挫湢頃� 747欤�, 2025雲� 3鞗� 10鞚检棎 鞚挫爠霅� 氚办毎鞛� 韽夓儩 鞝戧芳 鞁犿儊(spousal lifetime access trust)鞐� 氤搓磤霅� 2,510欤� 霌膘潣 臧勳爲 氤挫湢 雮挫棴霃� 瓿店皽霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潃 旮堨爠鞝� 鞚挫澋鞚� 氩旍渼毳� 齑堦臣頃橃 鞎婋姅 頃� 鞁れ鞝� 靻岇湢甓岇潉 欤检灔頃橃 鞎婌姷雼堧嫟.
Daniel Skovronsky, EVP, Chief Scientific Officer et pr茅sident de LRL & LLY Imm chez Eli Lilly & Co (LLY), a d茅clar茅, le 08/12/2025, l'achat de 1,000 actions ordinaires sur un Formulaire 4. L'op茅ration est cod茅e P (achat) au prix moyen pond茅r茅 de $634.405, avec des prix d'ex茅cution allant de $634.21 脿 $634.42. Apr猫s cet achat d茅clar茅, le d茅p么t indique que 137,660.112 actions sont d茅tenues directement. Le dossier r茅v猫le 茅galement des avoirs indirects de 72,359 actions par un trust, de 747 actions par le conjoint de la personne d茅clarante, et de 2,510 actions d茅tenues dans un spousal lifetime access trust transf茅r茅 le 10 mars 2025. Le d茅clarant d茅cline toute qualit茅 de propri茅taire b茅n茅ficiaire, sauf dans la mesure d'un int茅r锚t p茅cuniaire.
Daniel Skovronsky, EVP, Chief Scientific Officer und Pr盲sident von LRL & LLY Imm bei Eli Lilly & Co (LLY), meldete am 08/12/2025 den Kauf von 1.000 Aktien Stammaktien in einer Form 4. Die Transaktion ist mit dem Code P (Kauf) gekennzeichnet, zum gewichteten Durchschnittspreis von $634.405, mit Ausf眉hrungspreisen zwischen $634.21 und $634.42. Nach dem gemeldeten Kauf weist die Meldung 137,660.112 Aktien als unmittelbar wirtschaftlich im Eigentum aus. Die Meldung offenbart zudem indirekte Best盲nde von 72,359 Aktien durch einen Trust, 747 Aktien durch den Ehepartner der meldenden Person und 2,510 Aktien, die in einem am 10. M盲rz 2025 眉bertragenen Spousal Lifetime Access Trust gehalten werden. Der Melder weist die wirtschaftliche Eigent眉merschaft zur眉ck, au脽er insoweit ein verm枚gensrechtliches Interesse besteht.
- None.
- None.
Insights
TL;DR Insider purchase of 1,000 shares increases direct holdings modestly; transaction is disclosed at a weighted average price of $634.405.
The Form 4 documents a P purchase of 1,000 shares on 08/12/2025 at a weighted average price of $634.405. Following the purchase the reporting person鈥檚 direct beneficial ownership is listed as 137,660.112 shares. The filing itemizes additional indirect holdings by trust and spouse. From a financial-analyst perspective this is a routine officer purchase disclosed under Section 16 and provides transparent detail on price range and holdings; the size of the purchase is small relative to the absolute number of shares reported as owned.
TL;DR Disclosure includes appropriate footnotes and indirect-ownership detail; the Form 4 appears complete and properly executed.
The filing includes clarifying footnotes: a weighted average price range for the purchase, a disclaimer of beneficial ownership except for pecuniary interest, and a note that 2,510 shares were transferred to a spousal lifetime access trust on March 10, 2025. The form is signed by an authorized filer. No derivative transactions are reported. The disclosures address indirect ownership channels and trustee arrangements, consistent with Section 16 reporting expectations.
Daniel Skovronsky, EVP, Chief Scientific Officer e Presidente di LRL & LLY Imm presso Eli Lilly & Co (LLY), ha segnalato l'acquisto in data 08/12/2025 di 1,000 azioni ordinarie nel Form 4. La transazione 猫 contrassegnata con il codice P (acquisto) a un prezzo medio ponderato di $634.405, con prezzi di esecuzione compresi tra $634.21 e $634.42. Dopo l'operazione, il deposito indica la propriet脿 diretta di 137,660.112 azioni. La stessa comunicazione riporta inoltre partecipazioni indirette di 72,359 azioni detenute da un trust, di 747 azioni dal coniuge della persona che effettua la comunicazione, e di 2,510 azioni detenute in un spousal lifetime access trust trasferito il 10 marzo 2025. Il dichiarante rinuncia alla titolarit脿 beneficiaria salvo nella misura dell'interesse patrimoniale.
Daniel Skovronsky, EVP, Chief Scientific Officer y Presidente de LRL & LLY Imm en Eli Lilly & Co (LLY), declar贸 la compra el 08/12/2025 de 1,000 acciones ordinarias en un Formulario 4. La operaci贸n est谩 codificada como P (compra) a un precio medio ponderado de $634.405, con precios de ejecuci贸n entre $634.21 y $634.42. Tras la compra se帽alada, la presentaci贸n muestra 137,660.112 acciones pose铆das directamente. El documento tambi茅n revela tenencias indirectas de 72,359 acciones por un trust, de 747 acciones por el c贸nyuge de la persona declarante, y de 2,510 acciones mantenidas en un spousal lifetime access trust transferido el 10 de marzo de 2025. El declarante renuncia a la titularidad beneficiaria salvo en la medida de un inter茅s pecuniario.
Daniel Skovronsky電� Eli Lilly & Co (LLY)鞐愳劀 EVP, Chief Scientific Officer 瓴� LRL & LLY Imm 雼措嫻 靷灔鞙茧靹� 08/12/2025鞐� Form 4鞐� 1,000欤�鞚� 氤错喌欤茧ゼ 毵れ垬頃� 靷嫟鞚� 鞁犼碃頄堨姷雼堧嫟. 瓯半灅電� 毵れ垬毳� 雮橅儉雮措姅 旖旊摐 P搿� 攵勲霅橃棃鞙茧┌ 臧�欷戫弶攴犼皜瓴╈潃 $634.405, 觳搓舶 臧�瓴╈潃 $634.21鞐愳劀 $634.42 靷澊鞓�鞀惦媹雼�. 鞁犼碃霅� 毵れ垬 鞚错泟 鞝滌稖靹滊鞐愲姅 歆侅爲鞝侅溂搿� 137,660.112欤�毳� 鞁れ 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 氍胳劀鞐愲姅 鞁犿儊鞚� 氤挫湢頃� 72,359欤�, 鞁犼碃鞛愳潣 氚办毎鞛愱皜 氤挫湢頃� 747欤�, 2025雲� 3鞗� 10鞚检棎 鞚挫爠霅� 氚办毎鞛� 韽夓儩 鞝戧芳 鞁犿儊(spousal lifetime access trust)鞐� 氤搓磤霅� 2,510欤� 霌膘潣 臧勳爲 氤挫湢 雮挫棴霃� 瓿店皽霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潃 旮堨爠鞝� 鞚挫澋鞚� 氩旍渼毳� 齑堦臣頃橃 鞎婋姅 頃� 鞁れ鞝� 靻岇湢甓岇潉 欤检灔頃橃 鞎婌姷雼堧嫟.
Daniel Skovronsky, EVP, Chief Scientific Officer et pr茅sident de LRL & LLY Imm chez Eli Lilly & Co (LLY), a d茅clar茅, le 08/12/2025, l'achat de 1,000 actions ordinaires sur un Formulaire 4. L'op茅ration est cod茅e P (achat) au prix moyen pond茅r茅 de $634.405, avec des prix d'ex茅cution allant de $634.21 脿 $634.42. Apr猫s cet achat d茅clar茅, le d茅p么t indique que 137,660.112 actions sont d茅tenues directement. Le dossier r茅v猫le 茅galement des avoirs indirects de 72,359 actions par un trust, de 747 actions par le conjoint de la personne d茅clarante, et de 2,510 actions d茅tenues dans un spousal lifetime access trust transf茅r茅 le 10 mars 2025. Le d茅clarant d茅cline toute qualit茅 de propri茅taire b茅n茅ficiaire, sauf dans la mesure d'un int茅r锚t p茅cuniaire.
Daniel Skovronsky, EVP, Chief Scientific Officer und Pr盲sident von LRL & LLY Imm bei Eli Lilly & Co (LLY), meldete am 08/12/2025 den Kauf von 1.000 Aktien Stammaktien in einer Form 4. Die Transaktion ist mit dem Code P (Kauf) gekennzeichnet, zum gewichteten Durchschnittspreis von $634.405, mit Ausf眉hrungspreisen zwischen $634.21 und $634.42. Nach dem gemeldeten Kauf weist die Meldung 137,660.112 Aktien als unmittelbar wirtschaftlich im Eigentum aus. Die Meldung offenbart zudem indirekte Best盲nde von 72,359 Aktien durch einen Trust, 747 Aktien durch den Ehepartner der meldenden Person und 2,510 Aktien, die in einem am 10. M盲rz 2025 眉bertragenen Spousal Lifetime Access Trust gehalten werden. Der Melder weist die wirtschaftliche Eigent眉merschaft zur眉ck, au脽er insoweit ein verm枚gensrechtliches Interesse besteht.
FAQ
What transaction did Daniel Skovronsky report on Form 4 for LLY?
How many Eli Lilly shares does the reporting person own after the transaction?
Are there any indirect holdings disclosed for Daniel Skovronsky?
What price range was reported for the purchased shares?
What is the reporting person鈥檚 role at Eli Lilly?
